EC Number   |
Protein Variants |
Reference |
|---|
   4.2.3.47 | L405V |
products are 1.9% 7-epi-sesquithujene, 8.1% (E)-alpha-bergamotene, 8.9% sesquiabinene A, 23.9% (E)-beta-farnesene, 0% gamma-curcumene, 9.7% zingiberene, 12.0% beta-bisabolene, 26.6% beta-sesquiphellandrene, 8.9% (E)-gamma-bisabolene |
716549 |
| 4.2.3.47 | L405V/Y373S |
products are 1.2% 7-epi-sesquithujene, 23.6% (E)-alpha-bergamotene, 17.7% sesquiabinene A, 53.0% (E)-beta-farnesene, 0% gamma-curcumene, 0.6% zingiberene, 1.3% beta-bisabolene, 2.6% beta-sesquiphellandrene, 0% (E)-gamma-bisabolene |
716549 |
| 4.2.3.47 | more |
generation the two cross-convergent mutants, TPS10-B73 L356F and TPS10-dip F356L, by site-directed mutagenesis. The mutated enzymes are heterologously expressed, purified and assayed with the substrate (E,E)-farnesyl diphosphate. The mutant enzyme TPS10-B73 L356F produces less cyclic compounds than the wild type TPS10-B73 and has a product spectrum nearly identical to that of the wild type allele TPS10-dip which contains a phenylalanine at position 356. Conversely, the mutation of phenylalanine 356 to leucine in TPS10-dip results in a product profile dominated by (E)-alpha-bergamotene that is very similar to that of TPS10-B73. These results demonstrate that phenylalanine at position 356 is responsible for the decreased production of cyclic compounds in TPS10-dip and TPS10-per |
700674 |
| 4.2.3.47 | Y373S |
products are 7.6% 7-epi-sesquithujene, 24.8% (E)-alpha-bergamotene, 18.2% sesquiabinene A, 38.5% (E)-beta-farnesene, 0% gamma-curcumene, 4.7% zingiberene, 2.5% beta-bisabolene, 3.7% beta-sesquiphellandrene, 0% (E)-gamma-bisabolene |
716549 |
